ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novartis last week offered to acquire the shares it does not already own of U.S. vaccines maker Chiron for $40 per share or $4.5 billion in cash. The Swiss drug company currently holds a 42.2% stake in Chiron.
The offer, announced Thursday, capped an up-and-down week for Chiron, which has experienced serious interruptions at vaccine plants in the U.K. and Germany over the past year.
Chiron's report of a favorable FDA inspection of its Liverpool, England, facility, where it manufactures the influenza vaccine Fluvirin for the U.S. market, was followed by word that FDA has approved a competing vaccine, GlaxoSmithKline's Fluarix, for the upcoming flu season. Last week, GSK also announced that it will purchase Wyeth's vaccine plant in Marietta, Pa.
A Novartis spokesman says his firm, which has held its stake in Chiron since 1995, considers vaccines a $10 billion-per-year world market in which there is a potential to develop blockbuster products. "We see a move from commodity vaccines into high-value products--preventative vaccines and therapeutic vaccines in areas such as cancer," he says.
Standard & Poor's analyst David Lugg says Novartis has "always spoken of [its stake in] Chiron as a strategic investment." The bid represents a 10% premium to the company's recent stock price, but Lugg notes that Chiron's stock had reached nearly $60 per share before its manufacturing problems.
Jennifer Chao, a senior analyst at Deutsche Bank, says the 10% premium offered by Novartis "represents the low end of an acceptable range of from $40 to $44 per share."
Novartis has been on an acquisition tear. It recently completed the acquisition of sister generic drugmakers Hexal and Eon Labs and earlier purchased the over-the-counter drug business of Bristol-Myers Squibb. In recent years it also has made overtures to drug industry rivals Aventis and Roche.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter